About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Cleveland | 345 Studies

Clinical Trials LymphomaCleveland

Lymphoma Clinical Trials in Cleveland

Find 345 clinical trials for lymphoma near Cleveland, Ohio. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Cleveland

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 301-320 of 345 trials

Active not recruitingA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaB-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT05451810·Mobile, Alabama and 71 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaTrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants.NCT05951959·Hackensack, New Jersey and 28 others

TerminatedStudy Evaluating TRU-015 in B-Cell Non-Hodgkin's LymphomaThis is a study to evaluate the safety and efficacy of TRU-015 in treatment of B-cell Non-Hodgkin's Lymphoma (NHL).NCT00521638·Duarte, California and 6 others

CompletedIbrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell LymphomaThis study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy.NCT02242097·Chicago, Illinois and 4 others

TerminatedA Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaThe purpose of this study is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of TAK-659 when administered in combination with bendamustine…NCT02954406·Tucson, Arizona and 12 others

CompletedA Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersThis is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor…NCT02643303·Atlanta, Georgia and 6 others

TerminatedGEN3014 Trial in Relapsed or Refractory Hematologic MalignanciesThe drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.NCT04824794·Hackensack, New Jersey and 51 others

Active not recruitingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialThis phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to…NCT04320888·Birmingham, Alabama and 173 others

TerminatedA Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)Part 1: Dose Escalation.NCT04718675·Birmingham, Alabama and 23 others

CompletedCombination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00002941·Birmingham, Alabama and 234 others

CompletedA Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)This study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the…NCT02588651·Detroit, Michigan and 3 others

CompletedDose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P MutationRecent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B…NCT02252146·Los Angeles, California and 11 others

TerminatedZandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior…NCT03768505·Tucson, Arizona and 114 others

CompletedVNP40101M in Treating Patients With Advanced or Metastatic CancerRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00049699·New Haven, Connecticut and 2 others

CompletedProleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade…NCT00045864·Tucson, Arizona and 32 others

RecruitingRituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy.NCT07225439·Cleveland, Ohio and 1 other

CompletedA Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell LymphomaThe purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with…NCT00426764·La Jolla, California and 89 others

CompletedA Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaThis is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia.NCT02723994·Birmingham, Alabama and 110 others

CompletedTraumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell TransplantationRATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem…NCT00080873·Birmingham, Alabama and 43 others

RecruitingTesting Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaThis phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by…NCT05633615·Tucson, Arizona and 94 others

PreviousPage 16 of 18Next

Other Conditions in Cleveland

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia